Cemiplimab-rwlc in Advanced Cutaneous Squamous Cell Carcinoma: a real-life experience in a French Dermatology Department.

Abstract

Cemiplimab-rwlc (CEMI), a programmed cell death protein 1 (PD-1) inhibitor, has demonstrated its efficacy for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) patients that has never been reported with chemotherapy and is currently recommended for the first-line treatment of patients with advanced CSCC by the European guidelines2 . However, real-life data and long-term survival data are lacking.